Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07677358 · ClinicalTrials.gov registry record · Phase 1
A Study to Learn How the Study Medicine Called Atirmociclib is Handled by the Body in People With Normal Liver Function and Different Levels of Liver Disease
A Phase 1 study, sponsored by Pfizer.
- Not yet
- Registry status
- Phase 1
- Development phase
- 28
- Enrollment target
NCT07677358 is a Phase 1 study that has not yet begun recruiting, run by Pfizer. The registered enrollment target is 28 participants.
The verdict
NCT07677358, a Phase 1 study, has not yet begun recruiting, sponsored by Pfizer.
- NOT YET RECRUITING
- Registry status
- Phase 1
- Development phase
- 28 participants
- Enrollment target
Study Summary
The purpose of this study to understand how the study medicine atirmociclib behaves in the body and how safe it is for people with different levels of liver health. The study is seeking participants who are: * Aged 18 years or older * Have a BMI of 17.5 to 40 kg/m2, and body weight more than 50 kg. * Have normal liver function or have stable mild, moderate, or severe liver disease Participants will receive study medicine by mouth. Blood samples will be collected to see how much of the medicine is in the body over time. This will help understand whether liver disease changes how the medicine is handled. Participants will be in the study for about 9 weeks. Those with normal liver function will stay in the clinic for about 7 days. People with liver disease will stay for about 9 days. After leaving the clinic, people may be contacted for follow-up. This may be done by phone or through a clinic visit.
Interventions
- DRUG Atirmociclib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2026-07-09 |
| Est. Completion | 2027-09-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07677358
The ClinicalTrials.gov registry entry for NCT07677358 describes a study currently listed as not yet recruiting, categorized as Phase 1. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Atirmociclib is the first listed.
NCT07677358 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07677358 about?
NCT07677358 is a clinical study titled "A Study to Learn How the Study Medicine Called Atirmociclib is Handled by the Body in People With Normal Liver Function and Different Levels of Liver Disease". The purpose of this study to understand how the study medicine atirmociclib behaves in the body and how safe it is for people with different levels of liver health. The study is seeking participants who are: * Aged 18 years or older * Have a BMI of 17.5 to 40 kg/m2, and body weight more than 50 kg...
What is the current status of trial NCT07677358?
This trial is currently not yet recruiting. It is a Phase 1 study. The enrollment target is 28 participants. The study started on 2026-07-09. Estimated completion is 2027-09-10.
What interventions are being tested in trial NCT07677358?
The interventions under investigation include: Atirmociclib (DRUG).
Who is sponsoring clinical trial NCT07677358?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.